# TABLE OF CONTENTS

Oral and poster presentations ................................................................. 2  
Poster Presentations ................................................................................. 2  
Author index .......................................................................................... 13
Hospital Pharmacists’ Day 2018
February 6, 2018
San Marco Village, Schelle, Belgium

© Vlaamse Vereniging van Ziekenhuisapothekers (VZA)

This publication contains the abstracts of oral and poster presentations in the field of hospital pharmacy presented at the ‘Hospital Pharmacists’ Day’ held by the Flemish Association of Hospital Pharmacists in Schelle (Belgium) on 6th February 2018.

For this event, twenty-seven abstracts were submitted. Six abstracts were accepted for both oral and poster presentation. Twenty-one abstracts were accepted for poster presentation. This publication contains nineteen abstracts for which the BJHP received approval for publication in the BJHP by the submitting author.

The best two posters presentations will be awarded the ‘Amgen Scientific Award for Hospital Pharmacists’.
ORAL AND POSTER PRESENTATIONS

OP 1 | Dosing renally cleared drugs in critically ill children: mind the trap of glomerular hyperfiltration! .............................................................. 3
OP 2 | Implementation of the first Medicines Information Service in Belgium: a pilot study. .... 3
OP 3 | Oral anticancer drugs: to crush or not to crush ........................................................ 4
OP 4 | The role of the front-office clinical pharmacist according to physicians and nurses: results of a structured questionnaire .......................................................... 4

POSTER PRESENTATIONS

PP 1 | Subtherapeutic voriconazole serum concentration: consult of a clinical pharmacist ........ 5
PP 2 | ‘Beestjes’ in de HLAF-kast? Het uitvoeren van een microbiologische omgevingsmonitoring bij de productie van steriele geneesmiddelen in de HLAF-kast .................................................... 5
PP 3 | Evaluation of recommendations provided by a multidisciplinary infectious diseases team as part of an antimicrobial stewardship program ................................................................. 6
PP 4 | Dubbele controle bij het toedienen van hoog-risico medicatie ........................................ 6
PP 5 | Evaluation of front and back office pharmaceutical interventions in a tertiary hospital: type, acceptance, clinical impact .............................................................................. 6
PP 6 | Therapietrouw bij dialyse: resultaten na één maand ................................................................ 7
PP 7 | Clinical Impact of unintended medication discrepancies for unplanned admissions .......... 8
PP 8 | Analyse van het gebruik van hypnosedativa in het Universitair ziekenhuis Gent .................. 8
PP 9 | Vancomycine tdm: it’s (not) complicated ............................................................................. 9
PP 10 | Infusion reactions related to antithymocyte globulin administration: retrospective study in a pediatric Stem Cell Transplantation Unit ................................................................. 9
PP 11 | Infusion reactions to intravenous immunoglobulins in pediatric patients with secondary hypogammaglobulinemia .................................................................................. 10
PP 12 | Optimalisatie van het klinisch pad malnutriëte ..................................................................... 11
PP 13 | Getting the most out of your medication distribution robot through continuous process improvements ................................................................................................................... 11
PP 14 | A retrospective analysis of pharmaceutical interventions concerning QT-prolongation and exploration of implementation of a validated risk score in a teaching hospital .................................................. 11
PP 15 | Therapeutic adherence of chronic myeloid leukemia patients to nilotinib or dasatinib in a Belgian university hospital: a pharmacist’s perspective ................................................... 12

The BJHP is not responsible for the scientific content/contribution. Authors have full responsibility.
INTRODUCTION
Glomerular hyperfiltration (GHF), defined as an elevated glomerular filtration rate (GFR), induces the enhanced elimination of circulating solute by the kidneys. Recently, this phenomenon has received increasing attention in critically ill adults. The incidence in this setting is high, varying between 28-65%. In case of treatment with renally eliminated drugs, GHF suggests that these patients may be at risk for subtherapeutic drug concentrations when using standard dosage schedules. To date, data on the incidence of GHF in critically ill children are scarce.

AIM
The primary objective of this study was to investigate the incidence of GHF in critically ill children. Secondly, risk factors for the development of GHF were identified.

METHODS
This study was a single center, prospective, observational study, conducted at the Ghent University Hospital, Belgium, enrolling patients between 1 month and 15 years of age. GFR was measured by means of a calculated 24 hours creatinine clearance (24h ClCr). Creatinine in serum and urine were determined using Jaffe’s reaction. GHF was defined as a GFR exceeding normal values for age plus two standard deviations. Logistic regression analysis was used to identify covariates for GHF.

RESULTS
Data were collected from 65 patients (median age 1.7 years, IQR 3.0). Overall, 84.6% of patients expressed GHF. The incidence slowly decreased during consecutive days after admission to the ICU. GHF patients had a median ClCr of 181.8 ml/min/1.73m² (IQR 78.9). Younger age and the absence of vasopressor support were found as independently associated factors with the development of hyperfiltration.

CONCLUSIONS
The incidence of GHF in critically ill children seems even higher compared to adults, using an age dependent definition. As GHF may lead to subtherapeutic treatment of renally eliminated drugs, early detection of patients at risk should be of main importance.

OP 1 | Dosing renally cleared drugs in critically ill children: mind the trap of glomerular hyperfiltration!

De Cock Pieter1, Van Der Heggen Tatjana2,3, Dhont Evelyn4, Boeykens Nicky4, Roelandt Karlien5, Leenknegt Benjamin2, Peperstraete Harlinde5, Delanghe Joris6, Vande Walle Johan1, De Paepe Peter2

1Department of Pharmacy Ghent University Hospital, Ghent; 2Heymans Institute of Pharmacology, Ghent University, Ghent; 3Department of Pediatrics, Ghent University Hospital, Ghent; 4Department of Pediatric Intensive Care, Ghent University Hospital, Ghent; 5Department of Laboratory Medicine, Ghent University Hospital, Ghent; 6Department of Pediatric Nephrology, Ghent University Hospital, Ghent


Deyaert Elise1, Collier Hilde1, Ligneel Claudine1, Cortoos Pieter-Jan1

1Pharmacy Department, University Hospital Brussels, Brussels

BACKGROUND AND AIM
Medication errors are a threat to patient safety and often caused by insufficient knowledge among healthcare professionals. Given limited clinical pharmacists’ presence on Belgian hospital wards, a pharmacy-led Medicines Information Service (MIS) can efficiently provide fast, accurate and objective medication-related information. In this study, we implemented a MIS in a major tertiary care Belgian hospital.

METHODS
Best practices were researched through literature and site visit in Charing Cross Hospital (London, UK). Secondly, hospital personnel was surveyed on medicines information needs. Our MIS was set up to centrally (single dedicated pharmacist, phone number and e-mail) receive medication-related questions with the option for additional clinical-pharmaceutical interventions. Implementation was accompanied by hospital-wide promotion. All enquiries were registered in the MiDatabank®. After 4 months, the MIS was evaluated by analysing enquiries and user satisfaction.

RESULTS
221 respondents to our survey found ‘drug administration/dosing’ (79.7%), interactions (69.6%) and ‘tablet crushing’ (49.7%) the major problematic topics. Physicians favoured drug review, patient education/counselling and interaction information while nursing preferred support on drug administration and tablet crushing. Between 09/01 and 09/05/2017, our MIS received 247 enquiries. Drug administration/dose-related questions (43.3%) were most prevalent, followed by drug choice/indication (10.5%), interactions (9.7%), IV-compatibility (8.5%) and tablet crushing (7.7%). 80.2% of enquiries were answered within 1 hour (median: 11 min.), 81% of users mentioned improved knowledge by contacting the MIS, with 59%, respectively 56% reporting positive patient outcomes and time savings. Our MIS scored high on accessibility, timeliness, comprehensiveness and quality. Regarding workload, current MIS activity corresponds to 0.4FTE pharmacist with mean overall cost calculated at €15.4/enquiry.

DISCUSSION & CONCLUSION
There is still a great need for fast and reliable medication-related information. We succeeded to set up a well-running MIS with high user satisfaction and positive impact on knowledge, time consumption and patient outcome. Future plans are to extend and standardize our MIS activities.

The BJHP is not responsible for the scientific content/contribution. Authors have full responsibility.
**OP 3 | Oral anticancer drugs: to crush or not to crush**

Van Nieuwenhuyse Tine¹, Devolder David¹, Tans Birgit¹, Spriet Isabel¹,²

¹Hospital Pharmacy Department, UZ Leuven, Leuven; ²Department of Pharmaceutical and Pharmacological Sciences, KU Leuven

**BACKGROUND**

Healthcare professionals, involved in the daily care of cancer patients, are faced with the growing issue using oral anticancer drugs in patients experiencing swallowing difficulties. The lack of commercially available oral liquid dosing forms might compromise initiating or prolonging necessary therapies in this patient population. Pharmacists are often challenged to provide liquid alternatives for oral drugs that have solely been made commercially as a solid formulation; therefore it is common practice to crush tablets or to prepare oral liquids from solid forms. When preparing liquids ex tempore, a number of requirements need to be fulfilled. In addition to chemical, physical and microbiological stability of the active ingredients, therapeutic and toxicological aspects should be the subject of review.

**OBJECTIVE**

The goal was to develop a guide for healthcare providers in order to assist them in providing scientific and up-to-date information for patients who are in need of special dosing forms.

**METHOD**

A literature search in PubMed/Medline was conducted. Also, the registration documents and relevant phase I and II data from the pharmaceutical industry, U.S. Food and Drug Administration and European Medicines Agency were used as a source of information.

**RESULTS**

An overview for healthcare providers was drafted. Seventy oral anticancer drugs that were available on the Belgian market at the moment of the development were included.

**Conclusion**

The development of a pocket guideline has increased the awareness and will be added to the standard of care as to improve safe medication use in patients with swallowing difficulties.

**METHODS**

We conducted an electronically available structured questionnaire consisting of five questions among physicians (practicing physicians, residents and medical students) and head nurses. Statements regarding the possible tasks of the clinical pharmacist – as described by the government – on admission, during hospital stay and at discharge, concerning provision of drug information and means of communication, were scored as “added value/priority”, “useful/no priority” or “no need for”. Drug classes and patient groups, on which the clinical pharmacist should focus, were indicated.

**RESULTS**

The overall response rate was 37.5% (93/248). Physicians and head nurses answered alike on the different statements. 62% of respondents assign evaluation of the drug history on admission - rather than the conduct itself - to the clinical pharmacist. During hospital stay, advising on drug therapy involving high-risk drugs and patient groups, should occur according to 82% of respondents. At discharge an active intervention is less priority. The clinical pharmacist should definitely be involved in drug protocols and education. Availability by phone and e-mail to answer questions from the ward team, is valued more than joining daily ward rounds. Our focus should be on anticoagulants, antimicrobial drugs, polymedicated and geriatric patients.

**DISCUSSION & CONCLUSION**

Physicians and nurses of our hospital acknowledge the added value of a clinical pharmacist in patient care. Advising on drug therapy of polymedicated patients involving anticoagulant or antimicrobial therapy, should be core business of the front-office clinical pharmacist. An advisory function is more needed than systematically performing tasks on the ward. However by doing so, a pro-active role as a multidisciplinary team member, whom is also visible for the patients, will not be fully addressed.

**OP 4 | The role of the front-office clinical pharmacist according to physicians and nurses: results of a structured questionnaire**

Von Winckelmann Sandrina¹, Montag Ilke², Muller Kristin¹, Verheyen Véronique¹

¹Pharmacy Department, Imelda Hospital, Bonheiden; ²Medical Department, Imelda Hospital, Bonheiden; ³Nursing and Paramedical Department, Imelda Hospital, Bonheiden

**BACKGROUND & AIM**

The front-office clinical pharmacist can fulfill different tasks on the wards. To cover the greatest drug-related needs and risks in our hospital with our future projects, the perception of physicians and nurses regarding these topics was obtained.

The BJHP is not responsible for the scientific content/contribution. Authors have full responsibility.
POSTER PRESENTATIONS

PP 1 | Subtherapeutic voriconazole serum concentration: consult of a clinical pharmacist

Benoit Karel1, De Keulenaer Julie1, Deryckere Sabine1, Vermis Karen1, Somers Annemie3
1Department of Pharmacy, Ghent University Hospital, Ghent

BACKGROUND
An 64-old immunocompromised patient developed an Aspergillus spp. infection (September 2017). The therapy of choice is voriconazole.(1) Therapeutic drug monitoring is routinely performed at the Ghent University Hospital, a therapeutic range of 2-5.5 mg/L is targeted. Despite multiple dose adjustments, serum concentrations were persistently subtherapeutic (< 2mg/L). Therefore, the clinical pharmacist was consulted.

AIM
To optimize the dosage and intake of voriconazole to achieve serum concentrations within the therapeutic range.

Method: A thorough literature review was conducted on the variable pharmacokinetics of voriconazole and possible serum concentration augmentation due to a drug-drug interaction by omeprazole.

RESULTS
Voriconazole exhibits intra- and interpatient variable non-linear pharmacokinetics and is extensively metabolized by CYP2C19 predominantly. Due to genetic polymorphism, ultra-rapid metabolizers (URM) are not able to achieve therapeutic serum concentrations. Also, drug-drug interactions can influence the serum concentration of voriconazole.(2) The administration of a CYP2C19-inhibitor, like proton pump inhibitors, can increase the serum concentration. The association with omeprazole can induce an increase of 39%. (3) The possibility of this patient being an URM is small, respected the previously therapeutic serum concentrations (2.0 mg/L - October). Compliance to therapy was checked, as well the dose regimen (4 mg/kg BID). Subsequently, dosage was increased (+70%) up to 600 mg twice daily (6.8 mg/kg). Therefore, the pharmacist recommended to associate omeprazole 40 mg once daily. (4) Four days after the association, the serum concentration was 2.9 mg/L. Later on, the serum concentration was closely monitored due to the unpredictable effect of this association.

DISCUSSION & CONCLUSION
The association of omeprazole led to lasting therapeutic serum concentrations. The administration of a CYP2C19-inhibitor, like proton pump inhibitors, can increase the serum concentration. The association with omeprazole can induce an increase of 39%. The possibility of this patient being an URM is small, respected the previously therapeutic serum concentrations (2.0 mg/L - October). Compliance to therapy was checked, as well the dose regimen (4 mg/kg BID). Subsequently, dosage was increased (+70%) up to 600 mg twice daily (6.8 mg/kg). Therefore, the pharmacist recommended to associate omeprazole 40 mg once daily. (4) Four days after the association, the serum concentration was 2.9 mg/L. Later on, the serum concentration was closely monitored due to the unpredictable effect of this association.

REFERENCES


PP 2 | ‘Beestjes’ in de HLAF-kast? Het uitvoeren van een microbiologische omgevingsmonitoring bij de productie van steriele geneesmiddelen in de HLAF-kast

Callewaert Stefrey1, Borghys Wim2, Van Schaeren Jef3
1Ziekenhuisapotheek, Gasthuis Zusters Antwerpen, Antwerpen

ACHTERGROND & DOELSTELLING
De GZA ziekenhuisapotheek beschikt niet over een cleanroom voor de productie van steriele geneesmiddelen. Een aseptische werkwijze wordt gehanteerd in de HLAF-kast type A in een niet-geclassificeerde achtergrondruimte. Met het oog op de PICS wetgeving werd een microbiologische omgevingsmonitoring uitgevoerd in de HLAF-kast om na te gaan in hoeverre de huidige productiesetting tegemoet komt aan de PICS aanbevelingen.

METHODOGEN

RESULTATEN
Van de 124 contactafdrukken waren 2 positief (3 CFU) voor en 0 positief (0 CFU) na de desinfectie bij de bereidingssessies. De visuele inspectie van de huidige reinigings- en desinfectietechnieken toonde een niet-uniforme uitvoering aan. Op de sedimentatieplaten bloeesteld aan de lucht werden 0 CFU afgelezen. Op de handschoen vingertop afdrukken werden 0 CFU afgelezen. SOPs werden opgesteld voor een periodieke microbiologische omgevingsmonitoring in de toekomst.

DISCUSSION & CONCLUSION
Met de huidige reinigings- en desinfectiemethode wordt na de desinfectie voldaan aan de PIC/S aanbeveling, namelijk 0 CFU in een graad A omgeving. De niet-uniforme uitvoering beïnvloedt de effectiviteit niet. De blootstellingsduur van de sedimentatieplaten was te kort zodat moeilijk een besluit kon
PP 3 | Evaluation of recommendations provided by a multidisciplinary infectious diseases team as part of an antimicrobial stewardship program

Capiau Andreas1, Craeye Sofie1, De Keulenaer Julie1, Deryckere Sabine1, Vermis Karen1, Callens Steffrey1, Huis in ‘t Veld Diana2, Temmerman Sarah1, Vandekerckhove Lino2, Vogelaers Dirk3, Boelens Jerina2, Claeys Geert2, Coorevits Liselot2, Conmyne Sabrina1, Somers Anнемie1, Buyle Franky1

1Department of Pharmacy, Ghent University Hospital, Ghent; 2Department of Microbiology, Ghent University Hospital, Ghent; 3Department of General Internal Medicine, Ghent University Hospital, Ghent

BACKGROUND & AIM
As part of an antimicrobial stewardship program a multidisciplinary infectious diseases team (MIT) was initiated in January 2011. The MIT consists of infectious diseases physicians, clinical microbiologists and clinical pharmacists. The objective of this study is to analyse the recommendations which have been provided by the MIT, the acceptance rate of the recommendations and to improve the performance of the MIT.

METHODS
A prospective, observational study was performed. Clinical pharmacists registered every recommendation during 58 non-consecutive days between March - July 2017. A standardised case record form was used. Recommendations were scored as accepted when the physician implemented the recommendation(s) within three days after the communication. Subsequently, recommendations concerning antimicrobial therapy were evaluated on the completeness of the written notes in the electronic patient file.

RESULTS
The MIT discussed 227 patients which led to 457 recommendations. Bone and prosthetic joint infections (18.5%), bloodstream infections (16.3%) and abdominal infections (13.8%) were most common. Seven types of recommendations could be distinguished: (1) continuation of current antimicrobial regimen [N=161 (35.2%)], (2) additional clinical investigations [N=100 (21.9%)], (3) dosing adjustments [N=24 (5.3%)], (4) discontinuation of antimicrobial therapy [N=31 (6.8%)], (5) switching from parenteral to oral formulations [N=15 (3.3%)] and (6) initiating [N=55 (12.0%)] or (7) changing [N=71 (15.5%)] the antimicrobial regimen with acceptance rates ranging between 74% and 100%. The written recommendations in the electronic patient file included posology, route of administration and duration of therapy in respectively 76.7%, 63.4% and 63.9%.

DISCUSSION & CONCLUSION
This study shows that the MIT generated a daily average of 7 recommendations with acceptance rates varying in function of the recommendation type. However, more efforts should be made to ensure a complete recommendation. Hence, a pre-designed text with specific sections will be developed to optimise and to standardise the notes in the electronic patient file.

PP 4 | Dubbele controle bij het toedienen van hoog-risico medicatie

De Gieter Kim1, Desmedt Marjoleine1
1Departement Apotheek, AZ Jan Portaels ziekenhuis, Vilvoorde

ACHTERGROND EN DOELSTELLING
Het AZ Jan Portaels ziekenhuis Vilvoorde heeft een ziekenhuisbreed beleid over hoog-risico medicatie (HRM). Het ziekenhuis beschouwt geconcentreerde elektrolytenoplossingen, sound- en lookalike geneesmiddelen, anticoagulantia, insulines, verdovende middelen en cytotactica, als HRM. Om de veiligheid te verhogen was een procedure nodig voor dubbele controle bij bereiden en/of toedienen. Een risico-analyse werd uitgevoerd voor alle HRM op de verschillende handelingen bij klaarmaken en toedienen, op beschikbaarheid van een antidotum, op eventuele monitoring na toedienen, etc. We concludeerden dat kans op schade bij de patiënt het grootst was na foutief bereiden en/of toedienen van geconcentreerde elektrolyten. Specifiek voor deze groep werd een procedure opgesteld, bestaande uit 3 processtappen: bereiding, controle van de bereiding door tweede persoon en controle voor toediening. Uitbreiding van deze procedure naar alle HRM, is de volgende stap na toetsing en bijsturing van deze processtappen op de werkvloer.

METHODE

RESULTATEN

DISCUSSION EN CONCLUSIE

PP 5 | Evaluation of front and back office pharmaceutical interventions in a tertiary hospital: type, acceptance, clinical impact

De Keulenaer Julie1, Vercruysse Karen1, Somers Anнемie1
1Pharmacy Dept., University Hospital Ghent, Ghent

BACKGROUND
Pharmacist’s recommendations are diverse and often complex.
The effect of the interventions on long-term must however still be determined. In the meantime, the patients' medication knowledge has increased from 51.1% to 67.9% (p<0.05).

The patients' medication knowledge was measured four weeks after an interdisciplinary medication review and medication reconciliation. The patients were advised to make their medication schedule available. In addition, patients were informed of their medication via a leaflet. In addition, patients were given both oral and written education about their medication. The patients received both oral and written education about their medication.

The literature on the barrier and the patient's medication knowledge is not relevant and well received by prescribers. The predominant DRPs were change of dose and/or administration time (29.6%; acceptance rate: 53.4%) and therapeutic drug monitoring (17.5%; acceptance rate: 61.5%). This clinical impact was mostly assessed as significant (53.9%). The pharmacists rated 2 recommendations as extremely significant and 2 as harmful.

The aim of this project is to improve patient adherence to medication via interventions that are relevant and well received by prescribers. The ZAIO developed a medication brochure in clear language. In addition, patients received a medication review and medication reconciliation. The patients included were 40 chronic dialysis patients in three ZNA sites, with a fixed pharmacy in their area

**METHODS**

A monocentric, retrospective observational study was performed. Recommendations retrieved from the database (February-December 2016) were evaluated to determine the type, the underlying drug-related problem (DRP) and acceptance rates. Clinical impact was evaluated through random selection of 58 cases and multidisciplinary evaluation by an expert-panel (two clinical pharmacists and two clinical pharmacologists) using a validated method.2

**RESULTS**

During 11 months 2426 pharmacological recommendations were recorded for 1704 patients. Since a recommendation can be formulated for more than one DRP, therefore a total of 3175 separate recommendations were identified (BO: 62.5%). Fifty three recommendations were not clear for interpretation (1.7%) and acceptation rate could not be determined for 101 recommendations (3.2%) (e.g. early discharge). 1757 recommendations (58.4%) were accepted (BO: 57.3%; FO: 59.5%), 1264 recommendations (41.6%) were not accepted (BO: 42.7%; FO: 40.5%). The predominant DRPs were inadequate dosing (30.3%; acceptance rate: 57.0%) and drug-drug interactions (14.8%; acceptance rate: 54.5%). The most reported types of recommendation were change of dose and/or administration time (29.6%; acceptance rate: 53.4%) and therapeutic drug monitoring (17.5%; acceptance rate: 61.5%).

**CONCLUSION**

Most pharmacological recommendations were formulated back-office (62.5%). Overall, a good acceptance rate (58.4%) was established, similar to those mentioned in the literature. FO recommendations were fewer, but show better acceptance rates. Clinical impact was assessed as significant by an expert-panel. Therefore, we can state that pharmaceutical recommendations are clinically relevant and well received by prescribers.

**REFERENCES**


**ACHTERGROND & DOELSTELLING**

25% tot 50% van de chronisch zieken zijn therapieonzelf. Dialysepatiënten zijn een kwetsbare groep wat betreft therapietrouw. Het doel van dit project is de therapietrouw te verbeteren via interventies door een ziekenhuisapotheek in opleiding (ZAI0) op maat van de patiënt.

**METHODEN**

40 chronische dialyse patiënten in drie ZNA sites, met een vaste huisapotheek, werden geïncludeerd. De ZAI0 voerde interventies uit op maat van de patiënt, bepaald via ABQ (Adherence Barriers Questionnaire), op week 0-4-12-20. Elke patiënt kreeg zowel mondeling als schriftelijk educatie rond zijn medicatie. De schriftelijke educatie gebeurde via een zelf ontwikkelde medicatiebrochure in ‘klare taal’. Bovendien werd er een medicatiereview en medicatieconciliatie uitgevoerd. De therapietrouw werd gemeten via MMAS-8 (Morisky Medication Adherence Scales) en via de aankoopgegevens van de huisapotheek. De kennis van de medicatie werd bepaald door de patiënt zijn medicatieschema te laten aanvullen.

**RESULTATEN**

Via medicatieconciliatie werden er gemiddeld 5.9 discrepanties bepaald. Van de 40 patiënten hadden 17 patiënten een patiënt gerelateerde, opzetelijke én onbedoelde barrière voor therapietrouw. 16 patiënten ondervonden een medicatie gerelateerde barrière en 7 een gezondheid gerelateerde barrière. Na vier weken was het aantal ‘hoog’ therapietrouw patiënten, gemeten via MMAS-8, gestegen van 30 naar 38 (27% verbetering) (p = 0.014). Er werd een verschil gemeten tussen de therapietrouw bepaald via zelfrapportering (MMAS-8) (75.0% hoog therapietrouw) en via de huisapotheek (16.7% ‘hoog’ therapietrouw). De medicatiekennis van de patiënten was na vier weken gestegen van 51.1% naar 67.9% (p<0.05).

**DISCUSSIE & CONCLUSIES**

Uit deze tussentijdse meting blijkt de nood van goede transmurale zorg bij dialyse patiënten. Na één maand van de studie bleek zowel de therapietrouw als de medicatiekennis gestegen te zijn. In de loop van de studie zal meer bepaald worden dat interventies en educatie op maat van de patiënt wonen. Het effect van de interventies op langere termijn moet echter nog bepaald worden.

**BIBLIOGRAFIE**

BACKGROUND AND AIM
Transition between different healthcare settings is a risk factor for unintended medication discrepancies in the patient’s medication list. Discrepancies have the potential to cause adverse drug events, therefore obtaining a complete medication list is very important when a patient is admitted to the hospital.
We aimed to evaluate the added value of a structured medication reconciliation at the Emergency Department by a pharmacy assistant.

METHODS
Pharmacy assistants performed a structured medication reconciliation for patients admitted to the Emergency Department. This medication list was compared with the list obtained by the physician to identify unintentional medication discrepancies. The clinical impact of the discrepancies was evaluated by a multidisciplinary team of 2 clinical pharmacists and 2 clinical pharmacologists.

RESULTS
During the study period (February – April 2016), a total of 279 (34.5%) unintentional medication discrepancies were identified for a total number of 808 drugs (113 patients). The most common type was omission of a drug (43.7%), followed by omission of frequency (17.2%) and omission of dose (14.7%). Drugs of the Alimentary tract and Metabolism, Cardiovascular system and Nervous System were associated with the highest discrepancy rate. There was a positive association between the number of discrepancies and the number of drugs per patient (p=0.002), information sources used (p=0.026) and the time needed to perform the reconciliation (p=0.001). A total of 6.5% discrepancies were evaluated as having potentially a very significant impact on patient’s health, 30.6% as having the potential to cause moderate clinical impact and 62.9% as potentially having a minor or no impact on health outcomes (kappa = 0.193).

DISCUSSION AND CONCLUSION
This study provides evidence that structured medication reconciliation by means of a structured method is useful in order to obtain a complete medication history, to avoid medication related problems and to guarantee the patient’s safety.

REFERENCE
ACHTERGROND EN DOELSTELLING
Overmatig en verkeerd gebruik van antimicrobiële middelen en het daaraan geassocieerde resistentieprobleem is een wereldwijde uitdaging. Optimalisatie van het gebruik van antimicrobiële middelen is noodzakelijk voor de beperking van resistentie, verbetering van klinische uitkomsten, beperking van toxiciteit en beheersing van kosten. Verschillende antimicrobiële stewardship interventies kunnen daarvoor worden toegepast. Dosisoptimalisatie en TDM van vancomycine zijn interventies waarbij de ziekenhuisapotheek een centrale rol speelt. In dit onderzoek werd geëvalueerd of de optimalisatie van vancomycine dosering en TDM een positief effect had op de compliantie met de klinische richtlijn, TDM parameters en klinische uitkomsten.

METHODEN
Het onderzoek werd uitgevoerd in het UZ Antwerpen, een tertiair ziekenhuis met 573 bedden, met goedkeuring van het ethisch comité (B300201730826). Na het opstellen van een klinische richtlijn werden verschillende persuasieve interventies toegepast voor implementatie, namelijk verspreiding van de richtlijn via e-mail, educatieve sessies en directe feedback aan de behandelende arts. Deze feedback werd gegeven na dagelijks overleg tussen de apotheek en de afdeling klinische chemie via een gezamenlijke registratietool voor patiënten met vancomycine therapie.

Om de impact van de implementatiestrategie te bepalen werden patiënten van een pre-implementatie groep (16 januari 2016 - 16 april 2016) vergeleken met een post-implementatiegroep (16 januari 2017 - 16 april 2017). Patiënten jonger dan 18 jaar, patiënten op intensieve zorgen en dialyse patiënten werden geëxcludeerd.

CATEGORISCHE VARIABLEN WORDEN IN IBM® SPSS® STATISTICS VERSIE 24 GETEST MET DE CHI-KWADRAAT TEST OF FISHER’s EXACT TEST. CONTINUE VERHANDELINGEN WORDEN GETEST MET EEN ONAFHANKELIJK student T-TEST INDEN ZE NORMAAL VERDEELD WEREN OF MET EEN MANN-WHITNEY U-TEST INDEN ZE NIET NORMAAL VERDEELD WEREN.

RESULTATEN
Er werden respectievelijk 72 en 68 patiënten geïncludeerd in de pre- en post-implementatiemultiplet. Het onderzoek toonde aan dat er een toename was van het aantal patiënten in de post-implementatiemultiplet wat betreft het toedienen van een ladingssdosis (56,9% vs. 92,6%; p=0,000), correcte berekening van een ladingssdosis (39,0% vs. 74,6%; p=0,000) en correcte berekening van een onderhoudssdosis (33,3% vs. 64,7%; p=0,000). Het aantal patiënten met een optimale dosering verbeterde bovendien ook na het invoeren van de klinische richtlijn (12,5% vs. 52,9%; p=0,000). In de post-implementatiemultiplet werden meer spiegels op een correct tijdstip bepaald (57,3% vs. 64,6%; p=0,044), waren meer spiegels therapeutisch (19,5% vs. 35,2%; p=0,000) en bereikten meer patiënten therapeutische spiegels (37,5% vs. 57,4%; p=0,019).

In beide groepen werd geconstateerd dat niet-therapeutische spiegels vaak op een incorrect tijdstip werden bepaald (53,0% vs. 53,6%; p=0,903). De mediane tijdssduur met een therapeutische spiegel was hoger in de post-implementatiemultiplet (0,0%±23,3% vs. 14,6%±44,7%; p=0,012).

DISCUSSIE EN CONCLUSIES
Na het implementeren van de klinische richtlijn werd vancomycine vaker correct gedoseerd en verbeterde de timing van de spiegelbepaling. Er waren meer therapeutische spiegels en meer patiënten die therapeutische spiegels bereikten. Tenslotte nam de mediane tijdssduur met een therapeutische spiegel toe.

REFERENTIES
for graft-versus-host-disease. Its use is complicated by infusion reactions (IR) and premedication is recommended. Close compliance with recommended infusion times may reduce the incidence and severity of IRs. The aim was to analyze the prevalence and severity of IRs by ATG in a pediatric Stem Cell Transplantation (SCT) population, to identify potential risk factors and to optimize our ATG administration protocol.

**METHODOLOGY**
A retrospective study of IRs during/after administration of ATG (Thymoglobuline®) (2.5 mg/kg/dose) in a pediatric SCT ward. All patients received paracetamol and methylprednisolone as premedication before each ATG administration. Specific recommendations with gradual increase of speed of ATG administration were compliant with the Summary of Product Characteristics and the hospital’s guidelines. Severity of IRs was classified according to the Common Terminology Criteria for Adverse Events. Race, blood type, underlying pathology, reported allergies (drug/non-drug), previous IVIG reaction and asthma/bronchial hyperactivity were recorded.

**RESULTS**
A total of 16 patients (5 male, 31.3%) were included (age 0.5-13.2 years, median age 6.8 years). They represented 64 administrations. IRs were observed in 15 out of 16 (93.8%) patients, representing 23/64 (35.9%) administrations. Of these, 21/23 reactions (91.3%) were classified as grade 1-2 reactions while 2/23 (8.7%) as grade 4. Fifteen out of 23 reactions (65.2%) were observed during the first infusion, while 7/23 (30.4%) during the second administration. Both grade 4 reactions (100.0%) were observed during the first ATG infusion. No other potential risk factors could be identified.

**CONCLUSION**
A high number of IRs was observed, especially during the first ATG administration. Based on these data and conform literature data, our protocol for administration of ATG was adapted with standard inclusion of an antihistaminic in addition to paracetamol and corticosteroids, at least during the first ATG administration.

---

**PP 11 | Infusion reactions to intravenous immunoglobulins in pediatric patients with secondary hypogammaglobulinemia**

Van Laethem Kevin¹, Bordon Victoria², Laureys Guy², Bauters Tiene¹.²

¹Department of Pharmacy, Ghent University Hospital, Ghent; ²Department of Pediatric Hemato-Oncology and Hematopoietic Stem Cell Transplantation, Ghent University Hospital, Ghent

**BACKGROUND**
Intravenous immunoglobulins (IVIGs) are frequently used to improve humoral immunity in patients with secondary hypogammaglobulinemia. Adverse events associated with their use are mostly mild and transient. The aim of this study was to determine the prevalence and degree of IVIG infusion reactions (IR) and to identify potential risk factors in a pediatric hemato-oncology and HSCT population.

**METHODOLOGY**
IVIGs (Multigam®) were administered at a standard dose of 400 mg/kg and with a gradual administration rate conform the hospital’s protocol for IVIG administration. IRs were classified according to the Common Terminology Criteria for Adverse Events. Race, blood type, underlying pathology, reported allergies (drug/non-drug), previous IVIG reaction and asthma/bronchial hyperactivity were recorded. Collected data were coded and analyzed (SPSS® Statistics version 24, IBM, New York, USA) using contingency- and frequency tables.

**RESULTS**
A total of 64 patients (29 males, 35 females) were included (median age 6.9 year, range 0.6-16.2) representing 309 administrations. IRs were reported in 23/64 patients (35.9%), representing 27/309 (8.7%) of administrations. Most of the reactions were observed during the first administration (12/27; 44.5%), 4/27 (14.8%) during the second, 3/27 (11.1%) during the third and 8/27 (29.6%) during subsequent administrations. Of 27 reported reactions, 24/27 (88.9%) were categorized as grade 1-2 reactions, and 3/27 (11.1%) as grade 3. No grade 4 reactions were observed. Potential risk factors included immune-hematological malignancies (9 out of 35 administrations in this population; 25.7%), previous reported drug-related allergies (with more than 3 drugs) (4 out of 20 events; 20.0%), and previous reported IVIG hypersensitivity (4 out of 12 administrations; 33.3%).

**CONCLUSION**
The administration of IVIG’s is considered to be well-tolerated with mostly grade 1-2 reactions. Further follow-up in larger population groups is necessary to confirm the observed potential risk factors.
### PP 12 | Optimalisatie van het klinisch pad malnutritie

Van Uffelen Elisabeth¹, Smits Ilse¹, Haverhals Sophie¹

¹Ziekenhuisapotheek, AZ Monica, Antwerpen

Het is geen nieuw gegeven dat ondervoeding nefast is voor het algemene welzijn van de gehospitaliseerde patiënt. Preventiecijfers tonen aan dat malnutritie een reëel probleem is in de Belgische ziekenhuizen. De identificatie en behandeling van patiënten met ondervoeding is een essentieel onderdeel in het aanbieden van kwaliteitsvolle en kostenbesparende zorg. In AZ Monica werden zowel de screening door de verpleegkundigen als het nutritioneel assessment door de diëtisten onvoldoende uitgevoerd. Bovendien werd de keuze van nutritionele interventie niet gestaafd door recente wetenschappelijke literatuur met als gevolg een hoog verbruik van TPN.

Er werd een centrale nutriëtpathoeker aangesteld voor de vorming van een ziekenhuisbreed klinisch pad malnutritie en, daaruit volgend, een optimaal voedingsbeleid in AZ Monica. Deze apotheker faciliteerde de multidisciplinaire communicatie tussen de directiedienst, IT-team, verpleegkundigen, diëtisten, artsen en apothekers. Dit zorgde voor een verhoogde motivatie van alle betrokken disciplines. Zo ontstond er een nauwe samenwerking met de diëtisten dankzij de aanwezigheid van de nutriëtpathoeker op maandelijkse vergaderingen. Met een gegarandeerde opvolging van risicopatiënten door de diëtisten werd de screening op malnutritie door de verpleegkundigen ziekenhuisbreed geïntroduceerd. Op de dienst intensieve zorgen werd een optimaal voedingsbeleid opgestart door de nutriëtpathoeker in samenwerking met de diëtiste, verpleegkundigen en intensivisten. Ook op administratief vlak was de nutriëtpathoeker waardevol voor de betrokken partijen. Er werden protocolen omtrent voeding (en geneesmiddelen) opgesteld, gebaseerd op recente wetenschappelijke richtlijnen, ter ondersteuning van de diëtisten en collega-apothekers. Om de communicatie met het IT-team en de doorstroom van cijfergegevens te vergemakkelijken, werd een key performance indicator over malnutritiegegevens opgesteld.

Er is een duidelijke bewustwording ontstaan in verband met het belang van malnutritie in het ziekenhuis en een tendens van kiezen voor een correcte nutritionele interventie. De nutriëtpathoeker zal zich in de toekomst te spitsen op het blijvend motiveren van de verpleegkundigen tot ziekenhuisbreed screening en uitbreiding van het voedingsbeleid op intensieve zorgen.

### PP 13 | Getting the most out of your medication distribution robot through continuous process improvements

Vantrappen Astrid¹, Dewez Patricia¹

¹Pharmacy Department, Europe Hospitals, Brussels

**BACKGROUND & AIMS**

Europe Hospitals is a general hospital with 720 beds on two sites. It was one of the first in Belgium (2012) to install a robot (Baxter Proud, one per site) to automate the medication distribution process. The objectives were twofold: lower risk of medication errors, and higher pharmacy productivity. In 2017 a continuous improvement program was started to bring the system to its next level of performance, covering also a third objective: greater assurance of medication efficacy.

**METHODS**

The weak spots related to medication errors were identified through a risk analysis of the robotized distribution process. The sources of time wastage were analyzed. 3-year consumption volumes and volatility of all tablets and capsules in the hospital formulary were analyzed. Drugs sensitive to humidity were identified.

**RESULTS**

Interventions were made in four areas: the selection of drugs to be distributed through the robot; modifications to the hospital formulary and electronic prescription system; the reconditioning of drugs handled by the robot; and equipment setup and maintenance. The specific interventions were very diverse. One example relates to look- and sound-alike drugs: these are preferably distributed to the robot in order to reduce the risk of mistakes. Another example is the reduction of the expiry period of reconditioned drugs from 1 year to 6 months in order to compensate for faster degradation. The third example is the use of multiple pictures of the same drug by the image recognition apparatus in order to have fewer false rejected bags.

**DISCUSSION & CONCLUSION**

Getting the most out of your medication robot requires continuous adaptations and improvements in drug selection and reconditioning. This is due to continual changes in the drugs supply, the hospital formulary and prescription habits on the one hand, and to shifting process bottlenecks on the other hand. The program goes on in 2018.

### PP 14 | A retrospective analysis of pharmaceutical interventions concerning QT-prolongation and exploration of implementation of a validated risk score in a teaching hospital

Vercruysse Karen¹, De Keulenaer Julie¹, De Backer Tom², Timmers Liesbeth², Boussery Koen³

¹Pharmacy Dept., University Hospital Ghent, Ghent; ²Cardiology Dept., University Hospital Ghent, Ghent; ³Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent

**OBJECTIVE**

Prolongation of the QT-interval (and risk of Torsade de Pointes (TdP)) is often drug-related. Our hospital guidelines advise an ECG when a patient is on at least 3 drugs (mentioned on a limitative list) known to prolong QT-interval, regardless of patient-related risk factors. The objective was to evaluate pharmaceutical interventions and to explore the implementation of a validated risk-score (RISQ-PATH)¹ in adults hospitalized in a tertiary hospital.

**METHODS**

A database of pharmaceutical interventions (Oct-Dec 2016) was used and clinical parameters from the patient’s medical files were obtained. The (non-)acceptance was checked (ECG 72h post intervention). For each patient the RISQ-PATH score was calculated. A panel of cardiologists was consulted to evaluate 30 randomly chosen cases and judge pharmaceutical
recommendations.

RESULTS
A total of 1149 prescriptions was evaluated (900 patients ≥ 18y). According to the current guideline, for 300/1149 (26.1%) medication orders, a recommendation should have been given. However, in only 36 (12.0%) this recommendation was mentioned in the patient’s file. Only 1 recommendation (2.8%) was accepted. Of the adult population, 740 (82.2%) had a RISQ-PATH model score of ≥0.035. Evaluating the cases, the panel scored most recommendations as significant or very significant (14/14; 9/14) and would fully accept or partially accept most of the recommendations (14/14; 12/14). For the 16 cases which did not receive a recommendation, both raters would have intervened more frequently than current guidelines advise.

CONCLUSION
To date, knowledge of clinical relevance of drug-related QT-prolongation and TdP is limited. Pharmaceutical recommendations are rather little given and poorly accepted. Identification of high-risk patients based on current guidelines is insufficient and the estimation of the patient specific risk is time consuming when using risk scores. Cardiologists would more frequently recommend an ECG and monitor electrolytes intensively for at risk patients. A more sensitive risk score could be developed in prospective research.

REFERENCES

**PP 15 | Therapeutic adherence of chronic myeloid leukemia patients to nilotinib or dasatinib in a Belgian university hospital: a pharmacist’s perspective**

Vermis Karen¹, Lesage Delphine¹, Mertens Sarah¹, Somers Annemie¹

¹Pharmacy, UZ Gent, Gent

BACKGROUND AND AIM
Success of oral therapy demands a huge responsibility of the patient to take his medication as prescribed. Studies with imatinib have proven that suboptimal responses were significantly higher in chronic myeloid leukemia (CML) patients with adherence rates below 90 %. This study wants to evaluate the therapeutic adherence of CML patients in UZ Gent.

METHOD
The Medication Possession Ratio (MPR) was calculated for dasatinib or nilotinib delivered from 1/1/2013 until 29/2/2016 to CML patients treated in UZ Gent.

RESULTS
Forty eight treatment periods were evaluated with lengths varying from 24 to 1164 days. Patients were adherent in 8 (44.4%) nilotinib and 12 (40.0%) dasatinib treatments. MPRs below 90 % were observed in 5 nilotinib and 2 dasatinib treatments. In 43.8 % of the treatments an excess of medication was delivered by the pharmacy, meaning that the patients got more refills than needed. The cost of the excess pills for some patients ranged from 16021,00 € (dasatinib) to 27073,53€ (nilotinib).

DISCUSSION AND CONCLUSION
This study showed that in 14.6 % of the treatments the patient did not have enough medication (< 90%) to adhere to the therapy as prescribed by the hematologist. However, an excess of refill was delivered by the pharmacy to almost half of the patients, but this doesn’t implicate good adherence. These results demonstrate the need for a tool to keep up the balance between the number of pills prescribed and the exact number necessary for therapy. These data should allow the clinical pharmacist to retrieve information from the patient concerning his behavioral pattern and contribute to the empowerment of the patient by positive feedback. In addition, it should reduce unnecessary costs by preventing excess delivery of expensive medication.

The BJHP is not responsible for the scientific content/contribution. Authors have full responsibility.
<table>
<thead>
<tr>
<th>Author Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bauters, T, 10, 10</td>
</tr>
<tr>
<td>Benoot, K, 5</td>
</tr>
<tr>
<td>Boelens, J, 6</td>
</tr>
<tr>
<td>Boeykens, N, 3</td>
</tr>
<tr>
<td>Bordon, V, 10, 10</td>
</tr>
<tr>
<td>Borghys, W, 5</td>
</tr>
<tr>
<td>Boussery, K, 11</td>
</tr>
<tr>
<td>Buylaert, W, 8</td>
</tr>
<tr>
<td>Buyle, F, 6</td>
</tr>
<tr>
<td>Callens, S, 6</td>
</tr>
<tr>
<td>Callewaert, A, 5</td>
</tr>
<tr>
<td>Capiau, A, 6</td>
</tr>
<tr>
<td>Claeyts, G, 6</td>
</tr>
<tr>
<td>Collier, H, 3</td>
</tr>
<tr>
<td>Commeye, S, 6</td>
</tr>
<tr>
<td>Coorevits, L, 6</td>
</tr>
<tr>
<td>Cortoos, P, 3</td>
</tr>
<tr>
<td>Craeye, S, 6</td>
</tr>
<tr>
<td>De Backer, T, 11</td>
</tr>
<tr>
<td>De Broe, S, 7</td>
</tr>
<tr>
<td>De Cock, P, 3</td>
</tr>
<tr>
<td>De Gieter, K, 6</td>
</tr>
<tr>
<td>De Keulenaer, J, 5, 6, 7, 11</td>
</tr>
<tr>
<td>De Paepe, P, 3, 8</td>
</tr>
<tr>
<td>Delanghe, J, 3</td>
</tr>
</tbody>
</table>